Long-term efficacy of 90Y-DOTATATE in patients with nonresectable pancreatic and small bowel neuroendocrine neoplasms. (August 2016)

• Record Type: Journal Article
• Authors: Rogowski, Wojciech; Wachuła, Ewa; Lewczuk, Anna; Buscombe, John R; Seklecka, Nina; Sankowski, Artur; Ćwikła, Jarosław B
• Is Part Of: Future oncology. Volume 12:Number 16(2016)
• Page Start: 1877
• Page End: 1885
• Publication Date: 2016-08
• Subjects: 90Y-DOTATATE therapy -- clinical and radiological response -- GEP-NET; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2016-0031
• Languages: English
• ISSNs: 1479-6694

Abstract

Aim: To determine the efficacy of 90 Y [DOTA 0, D-Phe 1, Tyr 3 ]-octreotate (DOTATATE) in 67 patients with pancreatic and small bowel neuroendocrine tumors (NETs).Patients & methods: The primary efficacy end point was overall survival (OS) and secondary end points were progression-free survival (PFS) and tumor response.Results: Median PFS in pancreatic and small bowel NETs was 25 and 28 months, respectively, and median OS was 42 and 38.5 months, respectively. No intergroup differences in median OS (p = 0.945) or PFS (p = 0.174) were found, also after adjustment for tumor origin, secretory status and grade, and patient's gender.Conclusion: 90 Y-DOTATATE may have similar efficacy in pancreatic and small bowel NETs. Better WHO performance status at baseline seems to be associated with more favorable outcomes.